ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying treatments for patients with life-limiting respiratory diseases. We have created a broad, customizable non-viral lipid nanoparticle (LNP) platform that enables us to deliver our therapies safely and effectively. The company’s pipeline includes lead programs for patients with life-limiting inherited respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The company is leveraging its proprietary LNP platform and nucleic acid technologies, utilizing both systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells.